Article Text

Download PDFPDF
Successful treatment of severe rheumatoid vasculitis by infliximab
  1. L Unger,
  2. M Kayser,
  3. H G Nüsslein
  1. I Medizinische Klinik, Krankenhaus Dresden-Friedrichstadt, Dresden, Germany
  1. Correspondence to:
    Professor H G Nüsslein, I Medizinische Klinik, Krankenhaus Dresden-Friedrichstadt, Friedrichstr 41, 01067 Dresden, Germany;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Rheumatoid vasculitis (RV) is a severe complication of rheumatoid arthritis (RA), which like a primary necrotising vasculitis can affect any organ but characteristically presents with painful cutaneous ulcers and systemic inflammation.1,2 Usually patients with refractory RA are affected who, therefore, had already undergone extensive immunosuppressive treatment. The prognosis is poor and most patients die from infectious complications, cardiac failure, or cerebral insult.3–6 Cyclophosphamide (CYC) is the preferred treatment but is often not well tolerated and does not contain the synovitis.3 We report the cases of three patients with RV who could not sufficiently be treated by CYC and steroids but responded very well to infliximab infusion therapy.


Case 1

A 48 year old male patient with longlasting RA was admitted …

View Full Text